Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues

Breast J. 2019 Nov;25(6):1310-1311. doi: 10.1111/tbj.13474. Epub 2019 Jul 23.
No abstract available

MeSH terms

  • Adult
  • Androstadienes* / administration & dosage
  • Androstadienes* / adverse effects
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / adverse effects
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Cancer Survivors / statistics & numerical data
  • Chemotherapy, Adjuvant / adverse effects
  • Chemotherapy, Adjuvant / methods
  • Drug Monitoring* / methods
  • Drug Monitoring* / standards
  • Estradiol / blood*
  • Female
  • Gonadotropin-Releasing Hormone / agonists*
  • Humans
  • Ovarian Function Tests* / methods
  • Ovarian Function Tests* / standards
  • Ovary / drug effects
  • Ovary / metabolism
  • Ovary / physiopathology
  • Premenstrual Syndrome / diagnosis
  • Tamoxifen* / administration & dosage
  • Tamoxifen* / adverse effects
  • Uterine Hemorrhage / diagnosis

Substances

  • Androstadienes
  • Antineoplastic Agents, Hormonal
  • Tamoxifen
  • Gonadotropin-Releasing Hormone
  • Estradiol
  • exemestane